Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.

Treatments by Mechanism

Top 12 mechanisms across 68 industry trials with a known mechanism of action.

See full pipeline →

Calcium channel

2 trials 2 active 1 sponsor

Endothelin Receptor Antagonist

24 trials 1 active 5 sponsors

Angiotensin 2 Receptor Blocker

9 trials 1 active 7 sponsors

Prostacyclin Receptor Agonist

7 trials 1 active 1 sponsor

Atypical Antipsychotic

1 trials 1 active 1 sponsor

AT1 receptor

7 trials 4 sponsors

Thiazide-like Diuretic

6 trials 2 sponsors

ETA/ETB

3 trials 1 sponsor

Dihydropyridine Calcium Channel Blocker

3 trials 1 sponsor

SGLT2

2 trials 2 sponsors

Thiazide Diuretic

2 trials 2 sponsors

PDE5

2 trials 1 sponsor

MoA derived from FDA pharmClassEpc when intervention matches an approved drug. Codenamed clinical-stage assets without an approved counterpart show "—" and aren't grouped here — they're still in the phase tables below.

Clinical Pipeline by Phase

1006 industry-sponsored trials across 240 sponsors

View full landscape →

Showing 100 of 126 trials (top 100 by completion date — export for full list)

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Glaukos Corporation	—	—	RECRUITING	2026-08	NCT06848946
AOP Orphan Pharmaceuticals AG	Generic treprostinil sodium + Standard of Care (Double Oral)	—	RECRUITING	2027-06	NCT06317805
Shenzhen Ausa Pharmed Co.,Ltd	Amlodipine besylate	Calcium channel	RECRUITING	2029-06-30	NCT04974151
Shenzhen Ausa Pharmed Co.,Ltd	Amlodipine besylate	Calcium channel	RECRUITING	2030-06-30	NCT04974138
Chong Kun Dang Pharmaceutical	telmisartan	Angiotensin 2 Receptor Blocker [EPC]	RECRUITING	2025-10-31	NCT06431477
Genuine Research Center, Egypt	Nerkardou (5 mg) & (10 mg)	—	RECRUITING	2025-04-01	NCT05880056
United Therapeutics	Parenteral Treprostinil	—	ACTIVE NOT RECRUITING	2026-04-30	NCT05203510
Yuhan Corporation	Telmisartan/Amlodipine/Chlorthalidone 40/5/12.5 mg	—	ACTIVE NOT RECRUITING	2026-02-28	NCT06041529
RECORDATI GROUP	Osilodrostat	—	NOT YET RECRUITING	2028-05	NCT07247162
Bayer	Adempas (Riociguat, BAY63-2521)	—	COMPLETED	2025-09-15	NCT02759419
Menarini International Operations Luxembourg SA	Nebivolol 5 mg	—	COMPLETED	2024-02-19	NCT06104423
Menarini International Operations Luxembourg SA	Nebivolol	—	COMPLETED	2022-11-15	NCT05513937
Hanmi Pharmaceutical Company Limited	Amlodipine 5mg	—	COMPLETED	2022-07-25	NCT03666351
United Therapeutics	Intravenous/Subcutaneous Treprostinil; Oral Treprostinil	—	COMPLETED	2022-05-11	NCT03497689
Menarini International Operations Luxembourg SA	Zofenopril	—	COMPLETED	2022-04-28	NCT05279807
Menarini International Operations Luxembourg SA	Zofenopril 30 mg	—	COMPLETED	2021-12-22	NCT05257148
Yuhan Corporation	Rosuampin 10/5mg	—	COMPLETED	2021-09-29	NCT03951207
Daewoong Pharmaceutical Co. LTD.	OLOMAX 20/5/5mg	—	COMPLETED	2021-07-06	NCT04120753
Yuhan Corporation	Duowell®	—	COMPLETED	2020-09-02	NCT03267329
Actelion	Selexipag	Prostacyclin Receptor Agonist [EPC]	COMPLETED	2020-02-10	NCT03078907
Bayer	Riociguat (Adempas, BAY63-2521)	—	COMPLETED	2020-01-29	NCT02891850
Chong Kun Dang Pharmaceutical	Cantabell Tab	—	COMPLETED	2020-01-28	NCT04521023
KRKA	Amlessa®	—	COMPLETED	2019-09-27	NCT03738761
Actelion	Macitentan	Endothelin Receptor Antagonist [EPC]	COMPLETED	2019-09-10	NCT02310672
Yuhan Corporation	Duowell®	—	COMPLETED	2019-06-07	NCT03474562
Sumitomo Pharma (Suzhou) Co., Ltd.	Arotinolol Hydrochloride	—	COMPLETED	2018-09-13	NCT02612298
Chong Kun Dang Pharmaceutical	Telminuvo®Tab. 40/2.5mg	—	COMPLETED	2018-03	NCT02231788
Actelion	Macitentan	Endothelin Receptor Antagonist [EPC]	COMPLETED	2017-10-25	NCT02382016
Boryung Pharmaceutical Co., Ltd	Fimasartan	—	COMPLETED	2017-05	NCT02495324
Neutec Ar-Ge San ve Tic A.Ş	S-NOR (s-amlodipine) 2,5 mg & 5 mg tablet	—	COMPLETED	2017-02-14	NCT03038451
Takeda	Azilsartan Medoxomil	—	COMPLETED	2016-11-15	NCT02517866
Dong-A ST Co., Ltd.	OROSARTAN® 5/160mg	—	COMPLETED	2016-09-08	NCT02433119
Bayer	Nifedipine (Adalat GITS, BAY1040)	—	COMPLETED	2016-08-08	NCT02413515
Bayer	Riociguat (Adempas, BAY63-2521)	—	COMPLETED	2016-07-16	NCT02191137
Boryung Pharmaceutical Co., Ltd	Fimasartan	—	COMPLETED	2016-06	NCT01736488
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	Sildenafil	—	COMPLETED	2016-05-20	NCT01642407
Novartis	amlodipine/valsartan	—	COMPLETED	2015-09	NCT02062645
Janssen Scientific Affairs, LLC	Canagliflozin	SGLT2	COMPLETED	2015-04	NCT01939496
Chong Kun Dang Pharmaceutical	Candemore tablet	—	COMPLETED	2014-10	NCT01682564
Shanghai Shyndec Pharmaceutical Co., Ltd.	nifedipine CR tablets (Xin Ran)	—	COMPLETED	2014-07	NCT02031861
Merck KGaA, Darmstadt, Germany	Bisoprolol	—	COMPLETED	2014-04	NCT01508325
United Therapeutics	Remodulin	—	COMPLETED	2014-03	NCT02847260
TSH Biopharm Corporation Limited	Amlodipine/Valsartan	—	COMPLETED	2014-03	NCT02058446
Lee's Pharmaceutical Limited	Aspirine	—	COMPLETED	2014-03	NCT02594410
Astellas Pharma China, Inc.	Perdipine injection	—	COMPLETED	2014-01	NCT01872039
Shenzhen Ausa Pharmed Co.,Ltd	Enalapril/folic acid	—	COMPLETED	2013-08	NCT00794885
Organon and Co	Losartan (+) amlodipine	—	COMPLETED	2013-04-22	NCT01277822
Novartis	Aliskiren	—	COMPLETED	2013-04	NCT01176032
Merck KGaA, Darmstadt, Germany	Bisoprolol	—	COMPLETED	2013-04	NCT01066039
Lee's Pharmaceutical Limited	Zanidip	—	COMPLETED	2013-03	NCT01520285
Novartis	Valsartan	Angiotensin 2 Receptor Blocker [EPC]	COMPLETED	2013-01	NCT01541189
Hanmi Pharmaceutical Company Limited	Amosartan® tab	—	COMPLETED	2013-01	NCT01828359
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company	Perindopril + amlodipine + if necessary, hydrochlorothiazide	—	COMPLETED	2012-11	NCT01101009
Novartis	Aliskiren	—	COMPLETED	2012-11	NCT01570686
GSK	current marketed FLOLAN (epoprostenol sodium)	—	COMPLETED	2012-05-16	NCT01462565
Forest Laboratories	Nebivolol	—	COMPLETED	2012-03	NCT01415531
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.	Caduet	Calcium channels/HMGCR	COMPLETED	2012-02	NCT01190007
Merck KGaA, Darmstadt, Germany	Bisoprolol	—	COMPLETED	2012-02	NCT01251146
Bayer	Nifedipine (Adalat, BAYA1040) and Valsartan	—	COMPLETED	2012-02	NCT01071122
Merck KGaA, Darmstadt, Germany	Bisoprolol	—	COMPLETED	2011-12	NCT01190436
Novartis	Aliskiren and HCTZ	—	COMPLETED	2011-10	NCT01056731
Merck KGaA, Darmstadt, Germany	Bisoprolol	—	COMPLETED	2011-10	NCT01079962
Novartis	Aliskiren	—	COMPLETED	2011-10	NCT00927394
Novartis	Valsartan and hydrochlorothiazide (HCTZ) - monotherapy	—	COMPLETED	2011-07	NCT00902304
Actelion	ACT-385781A (Actelion Epoprostenol)	—	COMPLETED	2011-07	NCT01105117
Actelion	ACT-385781A (Actelion Epoprostenol)	—	COMPLETED	2011-05	NCT01105091
Bayer	Adalat (Nifedipine, BAYA1040)	—	COMPLETED	2011-05	NCT00993109
Forest Laboratories	nebivolol and lisinopril (free combination)	—	COMPLETED	2011-05	NCT01218100
Novartis	Valsartan/Amlodipine	—	COMPLETED	2011-04	NCT01167153
Jiangsu Simcere Pharmaceutical Co., Ltd.	Levamlodipine besylate	—	COMPLETED	2011-03	NCT01131546
Gilead	Ambrisentan	Endothelin Receptor Antagonist [EPC]	COMPLETED	2011-02	NCT00617305
Novartis	valsartan/amlodipine	—	COMPLETED	2011-01	NCT01241487
Novartis	Aliskiren	—	COMPLETED	2011-01	NCT01042392
Forest Laboratories	Nebivolol	—	COMPLETED	2010-12	NCT01057251
Novartis	Aliskiren/Amlodipine (150/5 mg/day, 300/10 mg/day) , Aliskiren/Amlodipine/Hydrochlorothiazide (300/10/12.5 mg/day, 300/10/25 mg/day)	—	COMPLETED	2010-10	NCT01070030
Novartis	Amlodipine 5mg/Valsartan 80 mg	—	COMPLETED	2010-09	NCT01070043
LaborMed Pharma S.A.	Hydrochlorothiazide	Thiazide Diuretic [EPC]	COMPLETED	2010-08	NCT00980187
Forest Laboratories	Nebivolol with concomitant losartan or lisinopril	—	COMPLETED	2010-07-09	NCT00673790
GE Healthcare	Optison (Perflutren Protein-Type A Microspheres Injectable Suspension)	—	COMPLETED	2010-07	NCT00878878
Forest Laboratories	Nebivolol	—	COMPLETED	2010-07	NCT00744237
Novartis	Aliskiren	—	COMPLETED	2010-06	NCT00865020
Takeda	Candesartan cilexetil and hydrochlorothiazide	Thiazide Diuretic [EPC]	COMPLETED	2010-05	NCT01012479
Boehringer Ingelheim	Telmisartan	Angiotensin 2 Receptor Blocker [EPC]	COMPLETED	2010-04	NCT00926289
United Therapeutics	Inhaled treprostinil	—	COMPLETED	2010-03	NCT00741819
Novartis	Aliskiren/Amlodipine	—	COMPLETED	2010-03	NCT00942994
Forest Laboratories	nebivolol	—	COMPLETED	2010-03	NCT00734630
Novartis	Amlodipine	—	COMPLETED	2010-01	NCT00787605
Daiichi Sankyo	olmesartan medoxomil	AT1 receptor	COMPLETED	2010-01	NCT00949884
Novartis	valsartan, amlodipine, HCTZ	—	COMPLETED	2010-01	NCT00931710
Novartis	Aliskiren	—	COMPLETED	2009-12	NCT00797316
Forest Laboratories	Nebivolol	—	COMPLETED	2009-11	NCT00770861
Organon and Co	losartan potassium	AT1 receptor	COMPLETED	2009-09-01	NCT00496834
Novartis	Aliskiren	—	COMPLETED	2009-09	NCT00631917
Forest Laboratories	Nebivolol	—	COMPLETED	2009-09	NCT00673075
Sanofi	Ramipril + Felodipine	—	COMPLETED	2009-09	NCT00841880
Novartis	Aliskiren	—	COMPLETED	2009-08	NCT00765947
Daiichi Sankyo	amlodipine and olmesartan medoxomil tablets	—	COMPLETED	2009-08	NCT00791258
Novartis	Aliskiren/Amlodipine	—	COMPLETED	2009-08	NCT00853957
Forest Laboratories	Nebivolol	—	COMPLETED	2009-08	NCT00785512
Novartis	Valsartan/aliskiren	—	COMPLETED	2009-07	NCT00809926

Showing 100 of 364 trials (top 100 by completion date — export for full list)

Sponsor	Asset	MoA	Status	Primary Completion	NCT
THPharm Corp.	THP-00101	—	RECRUITING	2026-06-01	NCT06647745
Sarfez Pharmaceuticals, Inc.	Combination Product: FDC of spironolactone and ER torsemide	—	RECRUITING	2026-07	NCT07223502
Qlaris Bio, Inc.	Latanoprost (0.005%)	—	RECRUITING	2026-07-01	NCT07354516
Tenax Therapeutics, Inc.	TNX-103	—	RECRUITING	2026-10	NCT05983250
Hanmi Pharmaceutical Company Limited	HGP2102-1	—	RECRUITING	2026-12-31	NCT06174766
Actelion	Macitentan	Endothelin Receptor Antagonist [EPC]	RECRUITING	2027-01-31	NCT05179876
Eli Lilly	Orforglipron	—	RECRUITING	2027-09	NCT06948422
Eli Lilly	Orforglipron	—	RECRUITING	2027-09	NCT06952530
Eli Lilly	Orforglipron	—	RECRUITING	2027-09	NCT06948435
Tenax Therapeutics, Inc.	TNX-103	—	RECRUITING	2028-06-30	NCT07288398
AOP Orphan Pharmaceuticals AG	preservative-free parenteral treprostinil	—	RECRUITING	2028-11	NCT06350032
Hanlim Pharm. Co., Ltd.	Test group	—	RECRUITING	2028-12	NCT07552389
Merck	Sotatercept	—	RECRUITING	2028-12-07	NCT07218029
Insmed Incorporated	Treprostinil Palmitil Inhalation Powder	—	RECRUITING	2028-12-30	NCT07179380
Inhibikase Therapeutics	IKT-001	—	RECRUITING	2029-06	NCT07365332
Liquidia Technologies, Inc.	L606	—	RECRUITING	2029-07	NCT07285655
Boehringer Ingelheim	Vicadrostat	—	RECRUITING	2029-12-14	NCT07064473
AstraZeneca	Baxdrostat/dapagliflozin	—	RECRUITING	2029-12-18	NCT06742723
Alnylam Pharmaceuticals	Zilebesiran	—	RECRUITING	2030-09-30	NCT07181109
JW Pharmaceutical	JW0104+C2402	—	RECRUITING	2026-04	NCT06643130
Chong Kun Dang Pharmaceutical	Sacubitril∙Valsartan(dose maintenance)	—	RECRUITING	2026-03-31	NCT06643819
Addpharma Inc.	AD-227A	—	RECRUITING	2025-09	NCT06441630
Pulnovo Medical (Wuxi) Co., Ltd.	Guideline-directed medical therapy (GDMT) for heart failure	—	RECRUITING	2025-08	NCT05824923
Addpharma Inc.	AD-224A	—	RECRUITING	2025-07	NCT06291207
Boryung Pharmaceutical Co., Ltd	BR1019A	—	RECRUITING	2025-04	NCT06220773
Addpharma Inc.	AD-209	—	RECRUITING	2025-02	NCT06348576
AJU Pharm Co., Ltd.	AJU-C52L, AJU-C52	—	RECRUITING	2022-12-12	NCT06416865
GB002, Inc.	Seralutinib	—	ACTIVE NOT RECRUITING	2026-12	NCT06274801
Insmed Incorporated	Treprostinil Palmitil	—	ACTIVE NOT RECRUITING	2026-12-31	NCT05649748
AstraZeneca	Baxdrostat/dapagliflozin	—	ACTIVE NOT RECRUITING	2028-02-24	NCT06268873
Mineralys Therapeutics Inc.	lorundrostat	—	ACTIVE NOT RECRUITING	2025-12-30	NCT05968430
Actelion	Macitentan 10 mg	—	ACTIVE NOT RECRUITING	2025-10-07	NCT04273945
Liquidia Technologies, Inc.	LIQ861 Inhaled Treprostinil	—	ACTIVE NOT RECRUITING	2025-05-31	NCT03992755
Liquidia Technologies, Inc.	—	—	ACTIVE NOT RECRUITING	2025-03-20	NCT04691154
Actelion	Selexipag	Prostacyclin Receptor Agonist [EPC]	ACTIVE NOT RECRUITING	2024-10-11	NCT04175600
Ablative Solutions, Inc.	Dehydrated alcohol	—	ACTIVE NOT RECRUITING	2023-12	NCT02910414
Bayer	Riociguat (Adempas, BAY63-2521)	—	ACTIVE NOT RECRUITING	2020-03-07	NCT02562235
Eurofarma Laboratorios S.A.	N0877	—	NOT YET RECRUITING	2028-04-30	NCT06608472
Insmed Incorporated	Treprostinil Palmitil Inhalation Powder	—	NOT YET RECRUITING	2028-12-28	NCT07481981
EMS	TCA108	—	NOT YET RECRUITING	2029-05	NCT07030101
Insmed Incorporated	Treprostinil Palmitil Inhalation Powder	—	NOT YET RECRUITING	2031-01-22	NCT07234032
Wuhan Createrna Science and Technology Co., Ltd	QR12000 75mg	—	NOT YET RECRUITING	2026-04-30	NCT06716970
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.	SYH9056	—	NOT YET RECRUITING	2026-03-30	NCT06771245
Insmed Incorporated	Treprostinil Palmitil Inhalation Powder	—	COMPLETED	2026-04-01	NCT05649722
Daewoong Pharmaceutical Co. LTD.	DWC202405	—	COMPLETED	2026-02-05	NCT06671392
United Therapeutics	Ralinepag	—	COMPLETED	2025-12-31	NCT03626688
GB002, Inc.	Seralutinib	—	COMPLETED	2025-11-27	NCT05934526
AstraZeneca	Baxdrostat	—	COMPLETED	2025-11-24	NCT06344104
Boryung Pharmaceutical Co., Ltd	BR1018A	—	COMPLETED	2025-11-11	NCT06165250
Daewoong Pharmaceutical Co. LTD.	DWC202404, DWC202314	—	COMPLETED	2025-10-02	NCT06682000
AstraZeneca	Baxdrostat	—	COMPLETED	2025-08-17	NCT06168409
Novartis	LCZ	—	COMPLETED	2025-05-28	NCT06236061
AstraZeneca	Baxdrostat	—	COMPLETED	2025-05-21	NCT06034743
Laboratorios Richmond S.A.C.I.F.	Treatment with nifedipine	—	COMPLETED	2025-04-15	NCT07448506
Addpharma Inc.	AD-223A	—	COMPLETED	2025-03-27	NCT06052748
Mineralys Therapeutics Inc.	lorundrostat Dose 1	—	COMPLETED	2024-12-10	NCT06153693
Hanmi Pharmaceutical Company Limited	HCP1803-3	—	COMPLETED	2024-12-02	NCT06438172
Boryung Pharmaceutical Co., Ltd	Fimasartan + Indapamide	—	COMPLETED	2024-12-02	NCT05878561
Otsuka Beijing Research Institute	OPC-1085EL	—	COMPLETED	2024-11-22	NCT05583474
Daewoong Pharmaceutical Co. LTD.	(D) DWC202206	—	COMPLETED	2024-09-10	NCT05643508
Boryung Pharmaceutical Co., Ltd	Fimasartan	—	COMPLETED	2024-09-05	NCT05930028
Actelion	Macitentan	Endothelin Receptor Antagonist [EPC]	COMPLETED	2024-08-28	NCT02932410
Janssen Pharmaceutical K.K.	Macitentan	Endothelin Receptor Antagonist [EPC]	COMPLETED	2024-08-23	NCT05167825
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA	Sotatercept	—	COMPLETED	2024-07-26	NCT04896008
Celltrion	AZM X mg + AML Y mg	—	COMPLETED	2024-07-11	NCT05385770
Kyungdong Pharmaceutical Co., Ltd.	KDF1901-R0	—	COMPLETED	2024-06-20	NCT07116863
Chong Kun Dang Pharmaceutical	D064, D702, placebo of D660	—	COMPLETED	2024-05-13	NCT05931224
Chong Kun Dang Pharmaceutical	D064 and D702, QD	—	COMPLETED	2024-03-22	NCT06121518
Merck	Sotatercept	—	COMPLETED	2024-03-12	NCT05818137
Celltrion Pharm, Inc.	Amlodipine	—	COMPLETED	2024-02-13	NCT07564726
Santen Pharmaceutical Co., Ltd.	STN1012600 ophthalmic solution 0.002%	—	COMPLETED	2024-01-30	NCT05503901
Merck	Frespaciguat	—	COMPLETED	2024-01-04	NCT04732221
Takeda	TAK-536	—	COMPLETED	2023-12-28	NCT04668157
Actelion	macitentan	Endothelin Receptor Antagonist [EPC]	COMPLETED	2023-12-27	NCT03422328
Shanghai Pharmaceuticals Holding Co., Ltd	SPH3127 tablet	—	COMPLETED	2023-12-26	NCT05359068
Hanmi Pharmaceutical Company Limited	HCP2102-1	—	COMPLETED	2023-12-11	NCT05450601
Shenzhen Salubris Pharmaceuticals Co., Ltd.	Allisartan Isoproxil/Sustained-Release Indapamide	—	COMPLETED	2023-11-27	NCT06500689
Actelion	Selexipag	Prostacyclin Receptor Agonist [EPC]	COMPLETED	2023-11-10	NCT04565990
George Medicines PTY Limited	Telmisartan 10 mg/amlodipine 1.25 mg/indapamide 0.625 mg	—	COMPLETED	2023-09-19	NCT04518306
Laboratorios Silanes S.A. de C.V.	Losartan/Chlorthalidone in fixed dose	—	COMPLETED	2023-08-15	NCT04927299
George Medicines PTY Limited	Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg	—	COMPLETED	2023-08-11	NCT04518293
Hanmi Pharmaceutical Company Limited	HCP1803-3	—	COMPLETED	2023-06-05	NCT05362110
Santen Pharmaceutical Co., Ltd.	STN1012600 ophthalmic solution 0.002%	—	COMPLETED	2023-04-18	NCT05495061
Laboratoires Thea	—	—	COMPLETED	2023-04-13	NCT04898387
Santen Pharmaceutical Co., Ltd.	A preservative-free, a clear, colorless sterile aqueous ophthalmic solution containing 0.015mg of tafluprost and 5.0mg of timolol in 1mL	—	COMPLETED	2023-04-04	NCT03822559
Handok Inc.	Irbesartan/Amlodipine low	—	COMPLETED	2023-04-03	NCT05476354
Handok Inc.	Irbesartan/Amlodipine	—	COMPLETED	2023-03-30	NCT05475665
JW Pharmaceutical	LivaloVA	—	COMPLETED	2022-11-08	NCT05331014
Hanmi Pharmaceutical Company Limited	HCP1904-3	—	COMPLETED	2022-09-14	NCT05199129
Quantum Genomics SA	Firibastat	—	COMPLETED	2022-08-30	NCT04277884
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA	Sotatercept	—	COMPLETED	2022-08-26	NCT04576988
Actelion	FDC macitentan/tadalafil	—	COMPLETED	2022-08-23	NCT03904693
Shenzhen Salubris Pharmaceuticals Co., Ltd.	Allisartan Isoproxil/Amlodipine group 1	—	COMPLETED	2022-08-16	NCT06465264
Santen SAS	DE-130A	—	COMPLETED	2022-02-03	NCT04133311
Santen Inc.	DE-117 Ophthalmic Solution	—	COMPLETED	2022-01-13	NCT03697811
Addpharma Inc.	AD-2021	—	COMPLETED	2021-11-22	NCT06448962
Hanmi Pharmaceutical Company Limited	HCP1904-1	—	COMPLETED	2021-09-30	NCT04820907
Actelion	ACT-293987	—	COMPLETED	2021-08-26	NCT01112306
Hanmi Pharmaceutical Company Limited	HCP1904-2	—	COMPLETED	2021-08-24	NCT04830449
United Therapeutics	UT-15C (treprostinil diolamine)	—	COMPLETED	2021-08-12	NCT01560637

Showing 100 of 251 trials (top 100 by completion date — export for full list)

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Fujian Shengdi Pharmaceutical Co., Ltd.	HRS-9563 Injection	—	RECRUITING	2026-07	NCT07297797
E-Star BioTech, LLC	MANP	—	RECRUITING	2026-07-01	NCT06343298
Retension Pharmaceuticals. Inc.	RTN-001	—	RECRUITING	2026-10	NCT07142356
Vanda Pharmaceuticals	iloperidone	Atypical Antipsychotic [EPC]	RECRUITING	2026-10	NCT07090161
Tectonic Therapeutic	TX000045- Dose A	—	RECRUITING	2026-10-09	NCT06616974
Pulmovant, Inc.	inhaled mosliciguat	—	RECRUITING	2026-12	NCT07333183
Kardigan, Inc.	Tonlamarsen	—	RECRUITING	2026-12-29	NCT07511361
Novartis	QCZ484	—	RECRUITING	2027-01-29	NCT06857955
AllRock Bio, Inc.	ROC-101	—	RECRUITING	2027-03	NCT07175038
AstraZeneca	Baxdrostat/dapagliflozin	—	RECRUITING	2027-05-24	NCT07222917
Apollo Therapeutics Ltd	APL-9796	—	RECRUITING	2027-08-30	NCT06846554
Regeneron	REGN13335	—	RECRUITING	2028-03-08	NCT07318597
Alnylam Pharmaceuticals	ALN-AGT01 RVR	—	RECRUITING	2028-04-01	NCT07553442
Foresee Pharmaceuticals Co., Ltd.	Mirivadelgat	—	RECRUITING	2028-06	NCT06475781
Pfizer	PF-07868489	—	RECRUITING	2028-07-18	NCT07073820
Merck	Sotatercept	—	RECRUITING	2028-09-21	NCT05587712
Novartis	LTP	—	RECRUITING	2028-11-29	NCT06649110
Merck	Sotatercept	—	RECRUITING	2029-03-30	NCT06814145
Shin Poong Pharmaceutical Co. Ltd.	SPC 1001 Mid2	—	RECRUITING	2025-10-08	NCT06826872
Pfizer	PF-07868489	—	ACTIVE NOT RECRUITING	2026-09-02	NCT06137742
Pulmovant, Inc.	Mosliciguat	—	ACTIVE NOT RECRUITING	2026-12	NCT06635850
GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.	GB002 (seralutinib)	—	ACTIVE NOT RECRUITING	2027-12	NCT04816604
Merck	Sotatercept	—	ACTIVE NOT RECRUITING	2028-06-16	NCT06925750
Merck	Frespaciguat	—	ACTIVE NOT RECRUITING	2026-04-09	NCT05612035
OrphAI Therapeutics	LAM-001	—	ACTIVE NOT RECRUITING	2025-05-16	NCT05798923
Actelion	selexipag (Uptravi)	—	ACTIVE NOT RECRUITING	2022-03-28	NCT03492177
Vincentage Pharma Co., Ltd	VCT220 Tablet	—	NOT YET RECRUITING	2026-10-20	NCT07360275
Qilu Pharmaceutical Co., Ltd.	Dose 1 of QLS1410	—	NOT YET RECRUITING	2026-12	NCT07489612
Boryung Pharmaceutical Co., Ltd	BR1400-1	—	NOT YET RECRUITING	2027-02-01	NCT07373613
Tectonic Operating Company, Inc.	TX000045	—	NOT YET RECRUITING	2027-11-21	NCT07473700
NS Pharma, Inc.	NS-863 Low Dose	—	NOT YET RECRUITING	2028-08-01	NCT07441200
NS Pharma, Inc.	NS-863 Low Dose	—	NOT YET RECRUITING	2028-09-14	NCT07441278
ARKAY Therapeutics	Metformin	—	NOT YET RECRUITING	2028-11-26	NCT03686657
BeBetter Med Inc	BEBT-701 Injection	—	NOT YET RECRUITING	2028-11-30	NCT07368608
Innovent Biologics (Suzhou) Co. Ltd.	IBI3016	—	NOT YET RECRUITING	2029-03-27	NCT07352969
Novartis	QCZ484	—	NOT YET RECRUITING	2031-05-31	NCT07543120
Kardigan, Inc.	Tonlamarsen	—	COMPLETED	2026-01-12	NCT06864104
Mineralys Therapeutics Inc.	Lorundrostat	—	COMPLETED	2025-12-17	NCT06785454
Merck	Sotatercept	—	COMPLETED	2025-11-20	NCT06664801
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA	Sotatercept 0.3 mg/kg	—	COMPLETED	2025-09-05	NCT04945460
Alnylam Pharmaceuticals	Zilebesiran	—	COMPLETED	2025-07-17	NCT06423352
AstraZeneca	AZD3427	—	COMPLETED	2025-07-15	NCT05737940
Bayer	Riociguat (Adempas, BAY63-2521).	—	COMPLETED	2025-07-03	NCT00694850
Alnylam Pharmaceuticals	Zilebesiran	—	COMPLETED	2025-06-19	NCT06272487
Insmed Incorporated	Treprostinil Palmitil	—	COMPLETED	2025-03-27	NCT05147805
Keros Therapeutics, Inc.	Dose A KER-012	—	COMPLETED	2025-03-05	NCT05975905
Mineralys Therapeutics Inc.	lorundrostat Dose 1	—	COMPLETED	2025-01-15	NCT05769608
Qlaris Bio, Inc.	QLS-111, 0.015%	—	COMPLETED	2024-12-20	NCT06249152
AstraZeneca	Baxdrostat	—	COMPLETED	2024-12-04	NCT06336356
Respira Therapeutics, Inc.	—	—	COMPLETED	2024-11-20	NCT04266197
Qlaris Bio, Inc.	Experimental: QLS-111 ophthalmic solution, (0.015%)	—	COMPLETED	2024-08-20	NCT06016972
Cereno Scientific AB	CS1 Administration	—	COMPLETED	2024-08-01	NCT05224531
Novartis	XXB750 drug	—	COMPLETED	2024-07-02	NCT05562934
AstraZeneca	CIN-107	—	COMPLETED	2024-05-02	NCT05432167
Insmed Incorporated	Treprostinil Palmitil	—	COMPLETED	2024-03-14	NCT05176951
Alnylam Pharmaceuticals	Indapamide	Thiazide-like Diuretic [EPC]	COMPLETED	2023-12-11	NCT05103332
Addpharma Inc.	AD-209	—	COMPLETED	2023-11-27	NCT05631990
AstraZeneca	CIN-107	—	COMPLETED	2023-11-07	NCT05459688
Altavant Sciences GmbH	rodatristat ethyl 300 mg tablet BID	—	COMPLETED	2023-06-05	NCT04712669
Alnylam Pharmaceuticals	ALN-AGT01	—	COMPLETED	2023-04-04	NCT04936035
Ionis Pharmaceuticals, Inc.	ION904	—	COMPLETED	2023-01-31	NCT05314439
Apnimed	AD113	—	COMPLETED	2023-01-31	NCT04905979
Shin Poong Pharmaceutical Co. Ltd.	SPC1001 High	—	COMPLETED	2022-11-27	NCT06212648
Shanghai Pharmaceuticals Holding Co., Ltd	SPH3127	—	COMPLETED	2022-10-24	NCT05593562
GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.	GB002 (seralutinib)	—	COMPLETED	2022-10-17	NCT04456998
CinCor Pharma, Inc.	CIN-107	—	COMPLETED	2022-09-13	NCT05137002
Mineralys Therapeutics Inc.	MLS-101 (Part I)	—	COMPLETED	2022-09-07	NCT05001945
Ionis Pharmaceuticals, Inc.	IONIS-AGT-LRx	—	COMPLETED	2022-06-29	NCT04714320
Vigonvita Life Sciences	TPN171H	—	COMPLETED	2022-06-29	NCT04483115
CinCor Pharma, Inc.	CIN-107	—	COMPLETED	2022-06-14	NCT04519658
GSK	Ambrisentan	Endothelin Receptor Antagonist [EPC]	COMPLETED	2022-06-09	NCT01342952
Actelion	Macitentan	Endothelin Receptor Antagonist [EPC]	COMPLETED	2022-03-21	NCT02060721
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA	Sotatercept	—	COMPLETED	2022-03-09	NCT03496207
Hanmi Pharmaceutical Company Limited	HCP1803-3	—	COMPLETED	2022-02-28	NCT04959305
Bial - Portela C S.A.	Oral zamicastat	—	COMPLETED	2022-02-17	NCT06009185
Ablative Solutions, Inc.	Alcohol	—	COMPLETED	2022-01-31	NCT03503773
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA	Sotatercept	—	COMPLETED	2021-12-21	NCT03738150
Handok Inc.	Irbesartan/Amlodipine	—	COMPLETED	2021-11-09	NCT04488978
Bial - Portela C S.A.	Oral zamicastat	—	COMPLETED	2021-10-20	NCT04316143
Bellerophon	—	—	COMPLETED	2021-09-07	NCT03727451
United Therapeutics	Ralinepag	—	COMPLETED	2021-03-29	NCT02279745
Addpharma Inc.	AD209	—	COMPLETED	2021-02-25	NCT04218552
KBP Biosciences	KBP-5074 0.25 mg tablet	—	COMPLETED	2020-08-05	NCT03574363
Ionis Pharmaceuticals, Inc.	ISIS 757456	—	COMPLETED	2020-07-20	NCT04083222
Shanghai Pharmaceuticals Holding Co., Ltd	SPH3127 tablet Dose 1	—	COMPLETED	2020-06-30	NCT03756103
Tenax Therapeutics, Inc.	Levosimendan	—	COMPLETED	2020-04-07	NCT03541603
Actelion	Macitentan 10mg	—	COMPLETED	2020-03-13	NCT02554903
Hanmi Pharmaceutical Company Limited	HCP1803	—	COMPLETED	2020-02-26	NCT03897868
Respira Therapeutics, Inc.	—	—	COMPLETED	2020-01-17	NCT05343637
Ionis Pharmaceuticals, Inc.	ISIS 757456	—	COMPLETED	2019-11-13	NCT03714776
Nicox Ophthalmics, Inc.	NCX 470	—	COMPLETED	2019-08-23	NCT03657797
Santen Inc.	DE-117 Ophthalmic Solution QD	—	COMPLETED	2019-06-20	NCT03858894
LongStar HealthPro, Inc. DBA Farlong Pharmaceutical	—	—	COMPLETED	2019-06-01	NCT04069715
GSK	GSK2586881	—	COMPLETED	2019-05-07	NCT03177603
Aerogen Pharma Limited	—	—	COMPLETED	2019-03-01	NCT03122730
Envisia Therapeutics	ENV515-3 Travoprost XR	—	COMPLETED	2019-02-13	NCT02371746
Relypsa, Inc.	Patiromer	—	COMPLETED	2018-11-27	NCT03071263
Bausch & Lomb Incorporated	brinzolamide 1% ophthalmic suspension	—	COMPLETED	2018-11-17	NCT03896633
Aerie Pharmaceuticals	AR-13324 Ophthalmic Solution 0.02%	—	COMPLETED	2018-10-25	NCT03310580
Quantum Genomics SA	QGC001	—	COMPLETED	2018-10-16	NCT03198793

Showing 100 of 265 trials (top 100 by completion date — export for full list)

Sponsor	Asset	MoA	Status	Primary Completion	NCT
Pharmosa Biopharm Inc.	L608 Liposomal inhalation suspension	—	RECRUITING	2026-06-30	NCT06429930
Zhejiang Yangli Pharmaceutical Technology Co., Ltd.	VB19055	—	RECRUITING	2026-07	NCT07254481
Beijing Continent Pharmaceutical Co, Ltd.	F230 tablets	—	RECRUITING	2026-07-01	NCT06899815
Eli Lilly	LY3971297	—	RECRUITING	2026-09	NCT06148272
Suzhou Alphamab Co., Ltd.	KN060	—	RECRUITING	2026-12-30	NCT07191899
Kyowa Kirin Co., Ltd.	KK3910	—	RECRUITING	2027-12	NCT06823947
Shenzhen Salubris Pharmaceuticals Co., Ltd.	SAL0140	—	RECRUITING	2026-01	NCT07051603
Fujian Shengdi Pharmaceutical Co., Ltd.	HRS-9563, placebo	—	RECRUITING	2025-12	NCT07117474
Bichedam Co., Ltd.	BCD101 Low Dose Liquid Formulation	—	RECRUITING	2025-09-23	NCT07282145
Neurotronic, Inc.	—	—	RECRUITING	2025-01	NCT05369065
Neurotronic, Inc.	—	—	RECRUITING	2025-01	NCT05363761
ADARx Pharmaceuticals, Inc.	ADX-850	—	ACTIVE NOT RECRUITING	2026-07-31	NCT06205628
PolyActiva Pty Ltd	—	—	ACTIVE NOT RECRUITING	2027-02-15	NCT06964061
Huons Co., Ltd.	HUC2-565-A, HUC2-565-A and HUC2-565-B	—	ACTIVE NOT RECRUITING	2024-07-12	NCT06618079
Boryung Pharmaceutical Co., Ltd	BR1015-A	—	NOT YET RECRUITING	2026-05-31	NCT07421375
Boryung Pharmaceutical Co., Ltd	BR1015-A	—	NOT YET RECRUITING	2026-06-07	NCT07421388
Boryung Pharmaceutical Co., Ltd	BR1015-A	—	NOT YET RECRUITING	2026-06-11	NCT07421401
Boryung Pharmaceutical Co., Ltd	BR1015-A	—	NOT YET RECRUITING	2026-06-17	NCT07421414
Addpharma Inc.	AD-231	—	NOT YET RECRUITING	2026-07	NCT07590167
Autotelicbio	ATB-U101	—	NOT YET RECRUITING	2026-07-31	NCT07590466
35Pharma Inc	HS235	—	NOT YET RECRUITING	2027-04	NCT07143448
35Pharma Inc	HS235	—	NOT YET RECRUITING	2027-09	NCT07123779
Innovent Biologics (Suzhou) Co. Ltd.	IBI3016	—	NOT YET RECRUITING	2027-10-16	NCT07556796
Qilu Pharmaceutical Co., Ltd.	QLS1410 (CYP11B2 inhibitor)	—	NOT YET RECRUITING	2026-05	NCT07152444
Shenzhen Salubris Pharmaceuticals Co., Ltd.	Sequence A T-R-T-R	—	NOT YET RECRUITING	2026-04-25	NCT07486453
Guangzhou Magpie Pharmaceuticals Co., Ltd.	MN-08 24 mg/day	—	NOT YET RECRUITING	2026-03-30	NCT05660863
Addpharma Inc.	Treatment A(AD-2321)	—	NOT YET RECRUITING	2026-02-11	NCT07312799
Qilu Pharmaceutical Co., Ltd.	QLS1410	—	NOT YET RECRUITING	2026-02-07	NCT07358858
Addpharma Inc.	Treatment A(AD-231A)	—	NOT YET RECRUITING	2026-02-07	NCT07312773
Gedeon Richter Plc.	Azilsartan medoxomil 80 mg tablet	—	NOT YET RECRUITING	2025-07-01	NCT06990204
Arnatar Therapeutics, Inc.	Subcutaneous (SC) single dose	—	COMPLETED	2025-12-19	NCT07529600
Bayer	BAY3283142	—	COMPLETED	2025-11-21	NCT06428825
Addpharma Inc.	Co-administration of AD-227A and AD-227B	—	COMPLETED	2025-08-13	NCT06884085
Boryung Pharmaceutical Co., Ltd	BR1018	—	COMPLETED	2025-07-23	NCT06889012
Bayer	BAY2701250 IV	—	COMPLETED	2025-05-20	NCT06048120
Suzhou Sanegene Bio Inc.	SGB-3908	—	COMPLETED	2025-04-07	NCT06501586
Boryung Pharmaceutical Co., Ltd	BR1015	—	COMPLETED	2025-03-19	NCT06744062
Boryung Pharmaceutical Co., Ltd	BR1015	—	COMPLETED	2025-03-16	NCT06744439
Boryung Pharmaceutical Co., Ltd	BR1015	—	COMPLETED	2025-03-14	NCT06744127
Boryung Pharmaceutical Co., Ltd	BR1015	—	COMPLETED	2025-03-12	NCT06744426
Humanis Saglık Anonim Sirketi	Selexipag Film Coated Tablets	—	COMPLETED	2025-03-03	NCT06932198
Boryung Pharmaceutical Co., Ltd	BR1019	—	COMPLETED	2024-12-11	NCT06636877
Hanlim Pharm. Co., Ltd.	Test group 1	—	COMPLETED	2024-11-15	NCT07568652
Boryung Pharmaceutical Co., Ltd	BR1400-1	—	COMPLETED	2024-10-08	NCT06889064
Novartis	QCZ484	—	COMPLETED	2024-09-25	NCT06905327
Pharmosa Biopharm Inc.	L608 Inhalation Solution	—	COMPLETED	2024-09-02	NCT05938946
Humanis Saglık Anonim Sirketi	Bosentan Dispersible Tablets	—	COMPLETED	2024-05-22	NCT06484673
Chong Kun Dang Pharmaceutical	CKD-341, D956	—	COMPLETED	2024-05-07	NCT06281132
Boryung Pharmaceutical Co., Ltd	BR1019	—	COMPLETED	2024-03-31	NCT06226727
Chong Kun Dang Pharmaceutical	CKD-348(6)	—	COMPLETED	2024-02-19	NCT06112678
Boryung Pharmaceutical Co., Ltd	BR1017-1	—	COMPLETED	2024-02-18	NCT06184269
Actelion	Prostacyclin Receptor Agonist	—	COMPLETED	2023-12-05	NCT05427162
THPharm Corp.	THP-00101 (Dapagliflozin) 10mg	—	COMPLETED	2023-11-09	NCT06063109
Boryung Pharmaceutical Co., Ltd	BR1015	—	COMPLETED	2023-10-06	NCT06008028
Boryung Pharmaceutical Co., Ltd	BR1015	—	COMPLETED	2023-10-03	NCT06008015
Chong Kun Dang Pharmaceutical	CKD-828, D064, D702	—	COMPLETED	2023-09-02	NCT05881707
Chong Kun Dang Pharmaceutical	CKD-341, D958	—	COMPLETED	2023-09-01	NCT05921435
United Therapeutics	Treprostinil Inhalation Powder	—	COMPLETED	2023-08-22	NCT03950739
Chong Kun Dang Pharmaceutical	CKD-828, D064, D701	—	COMPLETED	2023-07-18	NCT05834595
Hanlim Pharm. Co., Ltd.	Test group 1	—	COMPLETED	2023-07-12	NCT07598968
Boryung Pharmaceutical Co., Ltd	BR1019-1	—	COMPLETED	2023-06-29	NCT05875259
Vicore Pharma AB	C106 solution	—	COMPLETED	2023-06-22	NCT05427253
Celltrion	L04RD1	—	COMPLETED	2023-06-12	NCT05993806
Brillian Pharma Inc.	Amlodipine Freeze-Dried Powder for Oral Solution 5 mg	—	COMPLETED	2023-04-17	NCT05808725
Humanis Saglık Anonim Sirketi	Riociguat film coated tablets	—	COMPLETED	2023-03-17	NCT06180096
Bayer	BAY3283142	—	COMPLETED	2023-01-03	NCT05491642
Chong Kun Dang Pharmaceutical	CKD-341	—	COMPLETED	2022-12-04	NCT05571813
Aerami Therapeutics	AER-901 Solution for Nebulization	—	COMPLETED	2022-12-02	NCT04903730
Chong Kun Dang Pharmaceutical	D064+D701	—	COMPLETED	2022-11-15	NCT05540912
E-Star BioTech, LLC	MANP	—	COMPLETED	2022-10-31	NCT05247528
Vigonvita Life Sciences	TPN171H single dose	—	COMPLETED	2022-10-25	NCT05208814
Boryung Pharmaceutical Co., Ltd	BR1018-1	—	COMPLETED	2022-10-17	NCT05460364
AstraZeneca	baxdrostat	—	COMPLETED	2022-09-20	NCT05966324
Aadi Bioscience, Inc.	nab-sirolimus	—	COMPLETED	2022-08-16	NCT02587325
Boryung Pharmaceutical Co., Ltd	BR1017-1	—	COMPLETED	2022-06-04	NCT05372380
Attgeno AB	PDNO	—	COMPLETED	2022-05-25	NCT04891354
Bayer	BAY1237592	—	COMPLETED	2022-04-24	NCT03754660
Alnylam Pharmaceuticals	ALN-AGT01	—	COMPLETED	2022-04-20	NCT03934307
AstraZeneca	baxdrostat	—	COMPLETED	2022-04-15	NCT05961397
Pfizer	Prazosin HCl 2mg	—	COMPLETED	2022-02-15	NCT04967443
Vigonvita Life Sciences	TPN171H	—	COMPLETED	2022-02-06	NCT05185011
AstraZeneca	baxdrostat	—	COMPLETED	2022-01-15	NCT05961384
Merck	Frespaciguat	—	COMPLETED	2022-01-12	NCT04370873
HK inno.N Corporation	Telmione plus 80/12.5mg	—	COMPLETED	2021-10-31	NCT05040880
Boryung Pharmaceutical Co., Ltd	BR1015-1	—	COMPLETED	2021-10-22	NCT05097794
Theravance Biopharma	Ampreloxetine	—	COMPLETED	2021-08-19	NCT04200573
GB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.	GB002	—	COMPLETED	2021-05-05	NCT03926793
AstraZeneca	CIN-107	—	COMPLETED	2021-04-30	NCT05470725
Gmax Biopharm Australia Pty Ltd.	GMA301 Injection	—	COMPLETED	2021-03-19	NCT04505137
Theravance Biopharma	Ampreloxetine <Dose A>	—	COMPLETED	2021-03-13	NCT04688632
Addpharma Inc.	AD-2101	—	COMPLETED	2021-01-20	NCT04600284
AstraZeneca	Metformin	—	COMPLETED	2020-12-12	NCT05526690
Merck	Frespaciguat	—	COMPLETED	2020-12-11	NCT03744637
Vigonvita Life Sciences	TPN171H	—	COMPLETED	2020-10-14	NCT05948644
Jiangsu HengRui Medicine Co., Ltd.	SHR0532	—	COMPLETED	2020-09-03	NCT03971929
AstraZeneca	baxdrostat (formerly CIN-107) oral solution	—	COMPLETED	2020-04-29	NCT05963009
Hanlim Pharm. Co., Ltd.	Twynsta	—	COMPLETED	2020-04-28	NCT04667624
Chong Kun Dang Pharmaceutical	CKD-348 F1	—	COMPLETED	2020-04-26	NCT04258865
AstraZeneca	CIN-107	—	COMPLETED	2020-04-03	NCT05500820
GSK	AMB new formulation (1 mg)	—	COMPLETED	2019-12-17	NCT04095286

Novel Drugs by Company (New molecular entities)

IDORSIA 1 drug

TRYVIO

APROCITENTAN

NDA 2024

Reformulations (72 drugs) Click to expand

Reformulations are FDA-approved versions of existing molecules in new dosage forms (e.g., oral solution vs tablet, extended-release vs immediate-release). They require a new NDA but use an already-proven active ingredient.